Pneumocystis jirovecii

Fungal infections in the brain aren't just the stuff of movies – Africa grapples with a deadly epidemic

Retrieved on: 
Donnerstag, Juli 13, 2023

I am a neurobiologist who has been studying fungal infections of the brain for 10 years.

Key Points: 
  • I am a neurobiologist who has been studying fungal infections of the brain for 10 years.
  • I was part of a team that recently published a review discussing the emergence, and re-emergence, of fungal infections in Africa, especially in sub-Saharan Africa.
  • We conclude that Africa is suffering from a silent, but costly, epidemic of fungal infections.

What are fungal infections?

    • For the greater part of the history of humankind, fungal infections were never a threat to human health.
    • Even then, our immune systems are quite capable of fighting against fungal infections.
    • Africa accounts for 67% of the global burden of HIV, and opportunistic fungal diseases are on the rise.

Some examples

    • Today, sub-Saharan Africa contributes about 73% of all global cases and deaths resulting from the disease.
    • Cryptococcal meningitis is caused by the fungus Cryptococcus neoformans, which is found in soil and bird droppings.
    • It first leads to the development of a lung infection and later a fatal brain infection.
    • Cryptococcal meningitis is a leading cause of adult meningitis in sub-Saharan Africa and it’s associated with almost 20% of all AIDS-related deaths.

Growing burden

    • While these factors are not unique to Africa, the burden of fungal diseases and the number of people who succumb to them is much greater.
    • The COVID pandemic seems to have made the global fungal burden worse.
    • COVID-induced lung damage, high blood sugar, and the steroids often used to treat it are all predisposing factors to black fungus infection.

But don’t we have antifungal drugs?

    • With poorly funded and overburdened healthcare systems, many African countries are not well prepared to deal with fungal infections.
    • Additionally, some of the WHO-recommended antifungal drugs – such as flucytosine – are unavailable in most African countries.

Management strategies


    Fungal threats are adding pressure to overburdened health systems with a limited arsenal of treatment options. Healthcare professionals, scientific researchers, policymakers and governments must address the gaps in the diagnosis and management of fungal infections. This will help to improve capacity to deal with them.

Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use

Retrieved on: 
Montag, Juni 12, 2023

The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.

Key Points: 
  • The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.
  • Applied BioCode’s Fungal Panel is intended for research use only and may be used in infectious disease research or pharmaceutical development.
  • “Applied BioCode is thrilled to announce our first release of an RUO panel under our new product strategy.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.

OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients

Retrieved on: 
Mittwoch, Juni 22, 2022

The publication highlights the ability of the Unyvero Hospitalized Pneumonia panel in detecting potential pneumonia pathogens earlier than culture or very early during an infection.

Key Points: 
  • The publication highlights the ability of the Unyvero Hospitalized Pneumonia panel in detecting potential pneumonia pathogens earlier than culture or very early during an infection.
  • This enables reliable and rapid diagnosis of pathogens of concern in these patients directly from native lower respiratory tract samples, and provides identification of bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.
  • In their new publication titled Evaluation of a pneumonia multiplex PCR panel for detection of bacterial respiratory tract pathogens from serial specimens collected from hospitalized COVID-19 patients 2, the investigators conducted a follow-up study aimed to examine the concordant and discrepant results comparing the Unyvero HPN and culture results for detection of microorganisms from serial specimens collected from the same patient.
  • This press release includes statements regarding the publication of results of a recent study of the Unyvero Hospitalized Pneumonia panel.

KVK Tech Inc., Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5mL Due to Temperature Abuse

Retrieved on: 
Freitag, August 6, 2021

NEWTOWN, Pa., Aug. 6, 2021 /PRNewswire/ --KVK Tech, Inc., is voluntarily recalling two lots of Atovaquone Oral Suspension, USP 750 mg/5mLto the consumer level.

Key Points: 
  • NEWTOWN, Pa., Aug. 6, 2021 /PRNewswire/ --KVK Tech, Inc., is voluntarily recalling two lots of Atovaquone Oral Suspension, USP 750 mg/5mLto the consumer level.
  • KVK Tech Inc., Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5mL Due to Temperature Abuse
    Exposure of Atovaquone Oral Suspension to extremely low temperatures, during shipment (the product is required to be protected from freezing temperatures), may result in changes to the effectiveness, appearance, taste and thickness of the liquid.
  • Severely immunocompromised patients who receive less effective Atovaquone Oral Suspension may experience inadequate treatment of serious and life-threatening infections.
  • Consumers with questions regarding this recall can contact KVK Tech at 215-579-1842 Ext: 6002 Monday Friday, 8:00 am 4:30 pm EST or [email protected] .

Key Publication of Clinical Study Demonstrates Unyvero Lower Respiratory Tract (LRT) Panel is Likely to Alter Antibiotic Management of Significant Numbers of Patients Presenting with Suspected Pneumonia

Retrieved on: 
Mittwoch, September 2, 2020

Antibiotics could have been optimized in 7.8% of patients through both de-escalation and expansion.

Key Points: 
  • Antibiotics could have been optimized in 7.8% of patients through both de-escalation and expansion.
  • Unyvero LRT BAL is the only FDA-cleared lower respiratory tract infection panel that includes Pneumocystis jirovecii, a causative agent of Pneumocystis pneumonia (PJP) and a key fungal pathogen often found in immunocompromised patients that can be difficult to diagnose.
  • This press release includes statements regarding the potential impact on antibiotic therapy regimen and clinical utility of the Unyvero LRT and LRT BAL cartridges.
  • We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Curetis Launches Unyvero LRT Panel for BAL Specimens in the U.S.

Retrieved on: 
Dienstag, Januar 14, 2020

The Company received 510(k) clearance of Unyvero LRT BAL panel by the U.S. FDA on December 20, 2019, and has taken all necessary steps for an immediate U.S. commercial launch.

Key Points: 
  • The Company received 510(k) clearance of Unyvero LRT BAL panel by the U.S. FDA on December 20, 2019, and has taken all necessary steps for an immediate U.S. commercial launch.
  • The LRT BAL panel will be commercially available to Curetis U.S. customers from the end of January onwards.
  • The Unyvero LRT BAL application is the first and only FDA-cleared molecular diagnostic pneumonia panel that includes Pneumocystis jirovecii.
  • With our newly launched Unyvero LRT BAL Application Cartridge, clinicians and hospitals can now also test bronchoalveolar lavage samples.

Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting

Retrieved on: 
Dienstag, September 3, 2019

The fourth poster describes efficacy and safety data from the Phase 2 DYNAMO evaluating COPIKTRA patients with refractory marginal zone lymphoma (MZL).

Key Points: 
  • The fourth poster describes efficacy and safety data from the Phase 2 DYNAMO evaluating COPIKTRA patients with refractory marginal zone lymphoma (MZL).
  • Continued approval in FL may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Cases of Pneumocystis jirovecii pneumonia (PJP) (1%) and cytomegalovirus (CMV) reactivation/infection (1%) occurred in patients taking COPIKTRA.
  • Hepatotoxicity: Grade 3 and 4 ALT and/or AST elevation developed in 8% and 2%, respectively, of patients receiving COPIKTRA (N=442).

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting

Retrieved on: 
Montag, Juni 17, 2019

Infections: Serious, including fatal (4%), infections occurred in 31% of patients receiving COPIKTRA (N=442).

Key Points: 
  • Infections: Serious, including fatal (4%), infections occurred in 31% of patients receiving COPIKTRA (N=442).
  • Median time to onset of any grade infection was 3 months, with 75% of cases occurring within 6 months.
  • Cases of Pneumocystis jirovecii pneumonia (PJP) (1%) and cytomegalovirus (CMV) reactivation/infection (1%) occurred in patients taking COPIKTRA.
  • Diarrhea or Colitis: Serious, including fatal (